• Explore /
  • Poster
  • / Subcutaneous epcoritamab with rituximab + lenalidomide (R<sup>2</sup>) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.

Abstract Video & Slides Poster

Authors

Lorenzo Falchi

Lorenzo Falchi

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY

Lorenzo Falchi , Sirpa Leppä , Bjorn E. Wahlin , Marcel Nijland , Jacob Haaber Christensen , Sven De Vos , Harald Holte , Kim M. Linton , Aqeel Abbas , Liwei Wang , Minh Dinh , Brian Elliott , David Belada

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Clinical Trial Registration Number

NCT04663347

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7524)

DOI

10.1200/JCO.2022.40.16_suppl.7524

Abstract #

7524

Poster Bd #

178

Abstract Disclosures

Similar Posters

First Author: Martin H. Dreyling

First Author: Ian W. Flinn

First Author: Andrew David Zelenetz

First Author: Nathan Hale Fowler